Vertex Pharmaceuticals (VRTX) said Monday that the European Commission has expanded the label for Kaftrio in cystic fibrosis to include patients 2 years and older who have at least one non-class I mutation in the cystic fibrosis conductance regulator gene.
The company said around 4,000 cystic fibrosis patients in the European Union are now eligible to receive the medicine.
Kaftrio, or ivacaftor/tezacaftor/elexacaftor, is administered in combination with ivacaftor to treat cystic fibrosis patients.
Vertex said eligible patients in Austria, Denmark, Ireland, Norway, Sweden and Germany are expected to have access to Kaftrio "shortly."
Price: 469.03, Change: -5.59, Percent Change: -1.18
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。